SIGA Technologies, Inc. Earnings Recaps
Q1 2026
May 8, 2026
SIGA Technologies' share price rose modestly by 2.1% following first-quarter results characterized by minimal product deliveries and continued operating losses, reflecting the business's inherent revenue variability but no immediate catalyst to drive stronger investor enthusiasm.
Key takeaways
- First-quarter product revenues were approximately $3 million, including $1 million from IV TPOXX deliveries to the SNS and $2 million from manufacturing technology transfer reimbursements.
- Research and development revenues totaled about $3 million, contributing to overall revenues.
- The company reported a pretax operating loss of roughly $5 million and a net loss of $3 million for the quarter, with fully diluted loss per share of $0.05.
- Strong liquidity remains a highlight, with cash of approximately $146 million and no debt as of quarter-end.
- A special cash dividend of $0.60 per share was declared and subsequently paid in April, reflecting prudent capital management amid steady government contract progress and efforts to grow international sales.
Q3 2025
Nov 7, 2025
SIGA Technologies reported a solid third quarter, with product revenues totaling approximately $86 million year-to-date, reflecting continued government engagement for smallpox antiviral procurement amid evolving bioterrorism concerns.
Key takeaways
- Year-to-date product revenue was approximately $86 million, driven by strong oral and IV TPOXX sales.
- Approximately $26 million in outstanding U.S. government orders, primarily for IV TPOXX, expected to be delivered in 2026.
- Ongoing discussions regarding future procurement of TPOXX highlight the U.S. government's commitment to bioterrorism preparedness amidst a pending government shutdown.
- SIGA is progressing on pediatric formulation development and an FDA submission for post-exposure prophylaxis (PEP) planned for 2026, despite some delays due to the shutdown.
- International sales opportunities are anticipated for 2026 as global health security strategies evolve in response to bioterrorism threats.